

(19) World Intellectual Property Organization
International Bureau



27 SEP 2004



(43) International Publication Date
2 October 2003 (02.10.2003)

PCT

(10) International Publication Number
WO 03/079968 A2

- (51) International Patent Classification⁷: **A61K**
- (21) International Application Number: **PCT/IL03/00251**
- (22) International Filing Date: **25 March 2003 (25.03.2003)**
- (25) Filing Language: **English**
- (26) Publication Language: **English**
- (30) Priority Data:
60/367,271 **26 March 2002 (26.03.2002)** **US**
- (71) Applicant (*for all designated States except US*): **YEDA RESEARCH AND DEVELOPMENT CO. LTD [IL/IL]**; at the Weizmann Institute of Science, P.O. Box 95, 76100 Rehovot (IL).
- (72) Inventors; and
- (75) Inventors/Applicants (*for US only*): **EISENBACH-SCHWARTZ, Michal [IL/IL]**; **5, Rupin Street, 76353 Rehovot (IL)**. **MIZRAHI, Tal [IL/IL]**; **21 Moshav Ge'alya, 76885 Moshav Ge'alya (IL)**.
- (74) Agent: **BEN-AMI & ASSOCIATES**; P.O. Box 94, 2 Pekeris Street, Beit Madaim, Park Tamar, 76100 Rehovot (IL).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— *without international search report and to be republished upon receipt of that report*

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: **USE OF AN ORGAN-SPECIFIC SELF-PATHOGEN FOR TREATMENT OF A NON-AUTOIMMUNE DISEASE OF SAID ORGAN**

(57) **Abstract:** An agent selected from: (a) a pathogenic self-antigen associated with a T-cell-mediated specific autoimmune disease of an organ; (b) a peptide which sequence is comprised within the sequence of (a); (c) a peptide obtained by modification of (b), by replacement of one or more amino acid residues by different amino acid residues, said modified peptide still being capable of recognizing the T-cell receptor recognized by the parent peptide but with less affinity; (d) a nucleotide sequence encoding (a), (b), or (c); and (e) T cells activated by a pathogenic self-antigen of (a), a peptide of (b), or a modified peptide of (c), can be used for treatment of a non- autoimmune disease, disorder or injury in said organ. For example, uveitogenic antigens or peptides thereof can be used for treatment of a non-autoimmune disease, disorder or injury in the eye.



WO 03/079968 A2